IL160105A0 - Vaccine for treatment of motor neurone diseases - Google Patents

Vaccine for treatment of motor neurone diseases

Info

Publication number: IL160105A0
Authority: IL; Israel
Prior art keywords: cop; vaccine; treatment; motor neurone; tyr
Prior art date: 2001-12-06

Application number

IL16010502A

Other languages

English (en)

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-06

Filing date

2002-12-05

Publication date

2004-06-20

2002-12-05 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2004-06-20 Publication of IL160105A0 publication Critical patent/IL160105A0/xx

Links

208000026072 Motor neurone disease Diseases 0.000 title abstract 3
229960005486 vaccine Drugs 0.000 title abstract 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
239000013543 active substance Substances 0.000 abstract 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
206010061818 Disease progression Diseases 0.000 abstract 1
206010056677 Nerve degeneration Diseases 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000005750 disease progression Effects 0.000 abstract 1
229930195712 glutamate Natural products 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

IL16010502A 2001-12-06 2002-12-05 Vaccine for treatment of motor neurone diseases IL160105A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33613901P	2001-12-06	2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en)	2001-12-06	2002-12-05	Vaccine and method for treatment of motor neurone diseases

Publications (1)

Publication Number	Publication Date
IL160105A0 true IL160105A0 (en)	2004-06-20

Family

ID=23314742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16010502A IL160105A0 (en)	2001-12-06	2002-12-05	Vaccine for treatment of motor neurone diseases

Country Status (23)

Country	Link
US (1)	US7351686B2 (de)
EP (1)	EP1429800B1 (de)
JP (1)	JP4542339B2 (de)
KR (1)	KR20040081431A (de)
CN (2)	CN1617736A (de)
AT (1)	ATE422362T1 (de)
AU (1)	AU2002353486B2 (de)
CA (1)	CA2469092C (de)
CY (1)	CY1109044T1 (de)
DE (1)	DE60231131D1 (de)
DK (1)	DK1429800T3 (de)
ES (1)	ES2322566T3 (de)
HU (1)	HU228207B1 (de)
IL (1)	IL160105A0 (de)
IS (1)	IS2670B (de)
MX (1)	MXPA04005537A (de)
NO (1)	NO336231B1 (de)
NZ (1)	NZ533356A (de)
PL (1)	PL205469B1 (de)
PT (1)	PT1429800E (de)
RU (1)	RU2303996C2 (de)
SI (1)	SI1429800T1 (de)
WO (1)	WO2003047500A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7399740B2 (en)	2001-06-28	2008-07-15	Yeda Research And Development Co. Ltd.	Poly-Glu,Tyr for neuroprotective therapy
WO2004060265A2 (en) *	2003-01-07	2004-07-22	Yeda Research And Development Co. Ltd.	Eye-drop vaccine containing copolymer 1 for therapeutic immunization
EP1684797A1 (de)	2003-11-12	2006-08-02	Yeda Research and Development Co. Ltd.	Vakzine und verfahren zur behandlung von neurodegenerativen erkrankungen
CA2548310C (en)	2003-12-09	2014-02-18	Yeda Research And Development Co. Ltd.	Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
CA2558380A1 (en) *	2004-03-03	2005-09-15	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and riluzole
RU2410115C2 (ru) *	2004-05-07	2011-01-27	Пептиммьюн, Инк.	Способы лечения заболеваний с помощью статистических сополимеров
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
CA2615506A1 (en) *	2005-07-15	2007-01-25	Novartis Ag	Pamps, pathogen associated molecular patterns
CN100448481C (zh) *	2006-06-22	2009-01-07	中国科学院遗传与发育生物学研究所	xCT蛋白及其编码基因的新用途
US8193147B2 (en)	2007-09-24	2012-06-05	Hadasit Medical Research Services & Development Ltd.	Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es)	2010-10-11	2017-02-23	Teva Pharmaceutical Industries Ltd.	Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
WO2012143924A1 (en)	2011-04-21	2012-10-26	Mapi Pharma Ltd.	Random pentapolymer for treatment of autoimmune diseases
AU2012323345A1 (en)	2011-10-10	2014-05-22	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2013084236A1 (en) *	2011-12-05	2013-06-13	Ben-Gurion University Of The Negev Research And Development Authority	Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als)
KR20140145173A (ko) *	2012-03-26	2014-12-22	예다 리서치 앤드 디벨럽먼트 캄파니 리미티드	알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
US20150238582A1 (en)	2012-09-10	2015-08-27	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
BR112019017724A2 (pt)	2017-03-26	2020-03-31	Mapi Pharma Ltd.	Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL36670A (en) *	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
US3849650A (en)	1973-03-29	1974-11-19	Picker Corp	Automatic x-ray inspection system
IL113812A (en) *	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
SE505316C2 (sv) *	1995-10-17	1997-08-04	Kenneth G Haglid	Användning av proteinet S-100b för framställning av läkemedel för nervceller
RU2211697C2 (ru) *	1996-09-27	2003-09-10	Гилфорд Фармасьютикалз Инк.	Способ лечения глутаматных расстройств
AU2868699A (en) *	1998-02-13	1999-08-30	Autoimmune, Inc.	Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
US20020072493A1 (en)	1998-05-19	2002-06-13	Yeda Research And Development Co. Ltd.	Activated T cells, nervous system-specific antigens and their uses
US20030108528A1 (en)	1998-05-19	2003-06-12	Michal Eisenbach-Schwartz	Activated t-cells, nervous system-specific antigens and their uses
CA2328612A1 (en)	1998-05-19	1999-11-25	Yeda Research And Development Co., Ltd.	Activated t cells, nervous system-specific antigens and their uses
EP1039929A1 (de)	1998-07-21	2000-10-04	YEDA RESEARCH AND DEVELOPMENT Co. Ltd.	Aktivierten t-zellen und deren verwendung
JP2003521448A (ja)	1998-07-23	2003-07-15	ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ	合成ペプチドおよび自己免疫疾患治療のための使用方法
RU2155063C1 (ru) *	1999-10-20	2000-08-27	Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии"	Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
EP1248643B1 (de) *	2000-01-20	2005-08-17	YEDA RESEARCH AND DEVELOPMENT Co. LTD.	Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
DE60116467T2 (de) *	2000-06-07	2006-11-02	Yeda Research And Development Co., Ltd.	Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
WO2002076503A1 (en) *	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7399740B2 (en) *	2001-06-28	2008-07-15	Yeda Research And Development Co. Ltd.	Poly-Glu,Tyr for neuroprotective therapy
US6835711B2 (en) *	2001-06-28	2004-12-28	Yeda Research And Development Co. Ltd.	Use of poly-Glu,Tyr for neuroprotective therapy

2002
- 2002-12-05 US US10/485,576 patent/US7351686B2/en not_active Expired - Lifetime
- 2002-12-05 RU RU2004120536/14A patent/RU2303996C2/ru not_active IP Right Cessation
- 2002-12-05 DE DE60231131T patent/DE60231131D1/de not_active Expired - Lifetime
- 2002-12-05 PL PL370070A patent/PL205469B1/pl unknown
- 2002-12-05 WO PCT/IL2002/000979 patent/WO2003047500A2/en not_active Ceased
- 2002-12-05 JP JP2003548761A patent/JP4542339B2/ja not_active Expired - Fee Related
- 2002-12-05 CA CA2469092A patent/CA2469092C/en not_active Expired - Fee Related
- 2002-12-05 CN CNA028277015A patent/CN1617736A/zh active Pending
- 2002-12-05 SI SI200230800T patent/SI1429800T1/sl unknown
- 2002-12-05 PT PT02788511T patent/PT1429800E/pt unknown
- 2002-12-05 AU AU2002353486A patent/AU2002353486B2/en not_active Ceased
- 2002-12-05 NZ NZ533356A patent/NZ533356A/en not_active IP Right Cessation
- 2002-12-05 DK DK02788511T patent/DK1429800T3/da active
- 2002-12-05 MX MXPA04005537A patent/MXPA04005537A/es active IP Right Grant
- 2002-12-05 ES ES02788511T patent/ES2322566T3/es not_active Expired - Lifetime
- 2002-12-05 IL IL16010502A patent/IL160105A0/xx unknown
- 2002-12-05 CN CN201110056639.8A patent/CN102151330B/zh not_active Expired - Fee Related
- 2002-12-05 HU HU0500039A patent/HU228207B1/hu not_active IP Right Cessation
- 2002-12-05 AT AT02788511T patent/ATE422362T1/de active
- 2002-12-05 EP EP02788511A patent/EP1429800B1/de not_active Expired - Lifetime
- 2002-12-05 KR KR10-2004-7008780A patent/KR20040081431A/ko not_active Ceased
2004
- 2004-06-03 IS IS7296A patent/IS2670B/is unknown
- 2004-07-05 NO NO20042833A patent/NO336231B1/no not_active IP Right Cessation
2009
- 2009-05-06 CY CY20091100485T patent/CY1109044T1/el unknown

Also Published As

Publication number	Publication date
SI1429800T1 (sl)	2009-08-31
PL205469B1 (pl)	2010-04-30
CN1617736A (zh)	2005-05-18
WO2003047500A2 (en)	2003-06-12
WO2003047500A3 (en)	2004-03-18
NZ533356A (en)	2006-10-27
DE60231131D1 (de)	2009-03-26
EP1429800A2 (de)	2004-06-23
RU2004120536A (ru)	2005-03-27
EP1429800A4 (de)	2006-03-22
DK1429800T3 (da)	2009-04-27
JP2005515198A (ja)	2005-05-26
NO336231B1 (no)	2015-06-22
ATE422362T1 (de)	2009-02-15
PT1429800E (pt)	2009-04-27
ES2322566T3 (es)	2009-06-23
MXPA04005537A (es)	2004-11-01
RU2303996C2 (ru)	2007-08-10
CA2469092C (en)	2013-02-19
PL370070A1 (en)	2005-05-16
CA2469092A1 (en)	2003-06-12
HUP0500039A2 (hu)	2005-03-29
HUP0500039A3 (en)	2010-01-28
EP1429800B1 (de)	2009-02-11
NO20042833L (no)	2004-08-12
CN102151330B (zh)	2017-04-12
HK1067043A1 (en)	2005-04-01
CY1109044T1 (el)	2014-07-02
IS7296A (is)	2004-06-03
AU2002353486B2 (en)	2009-01-15
AU2002353486A1 (en)	2003-06-17
KR20040081431A (ko)	2004-09-21
US7351686B2 (en)	2008-04-01
CN102151330A (zh)	2011-08-17
US20050220802A1 (en)	2005-10-06
JP4542339B2 (ja)	2010-09-15
HU228207B1 (hu)	2013-01-28
IS2670B (is)	2010-09-15

Publication	Publication Date	Title
EP1429800A4 (de)	2006-03-22	Vakzine und verfahren zur behandlung von motorischen neuronenerkrankungen
AU6185398A (en)	1998-10-20	Charged lipids and uses for the same
EA200601132A1 (ru)	2007-02-27	Предупреждение и лечение амилоидогенного заболевания
AU6762794A (en)	1995-02-06	A coagulation factor viii formulation
WO2002100390A3 (en)	2004-04-22	Improved method of treating the syndrome of coronary heart disease risk factors in humans
TW200509968A (en)	2005-03-16	Prevention and treatment of synucleinopathic disease
MXPA05002814A (es)	2005-05-27	Formulacion para agentes lipofilicos.
ZA200209982B (en)	2003-03-24	Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotogotine.
PL312219A1 (en)	1996-04-01	Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
UA88270C2 (ru)	2009-10-12	Фармацевтический препарат и его применение для профилактики удара, диабета
MXPA05006572A (es)	2005-12-14	Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad.
CA2299361A1 (en)	1999-02-25	Use of consensus interferon in combination with il-1 receptor antagonist for treatment of patients afflicted with multiple sclerosis
EP0834320A4 (de)	2000-11-22	Wirkstoff-zusammensetzung, die albumin als aktiven bestandteil erhaelt
MY118526A (en)	2004-11-30	Method for improving the pharmacokinetics of tipranavir
NZ516477A (en)	2004-02-27	Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
AU7242796A (en)	1997-04-09	Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
MXPA02005563A (es)	2004-09-10	Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
CA2225788A1 (en)	1997-01-23	Therapeutic agents and autoimmune diseases
MX9707642A (es)	1997-12-31	Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
WO2002046225A3 (en)	2004-01-08	Use of sarp-1 for the treatment and/or prevention of scleroderma
MXPA02011533A (es)	2003-04-25	Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NZ505538A (en)	2004-12-24	A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
AU2001267864A1 (en)	2002-01-08	Remedial agent for optic nerve disease and the like
AU3739500A (en)	2000-10-16	Protease resistant flint analogs
WO2003026570A3 (en)	2004-01-22	Reduced toxicity cisplatin formulations and methods for using the same